The coordinated inhibition of HDAC6, HDAC3, and HDAC4 by BKS-112 may synergistically contribute to its potent anticancer effects, as these isoforms play distinct but complementary roles in cancer cell survival and progression. The gene discussed is HDAC6; the disease is cancer.